Privia Health Group (NASDAQ:PRVA) CFO Sells $133,134.36 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 5,829 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $22.84, for a total value of $133,134.36. Following the sale, the chief financial officer owned 161,903 shares in the company, valued at $3,697,864.52. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

David Mountcastle also recently made the following trade(s):

• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total value of $192,809.85.
• On Friday, December 12th, David Mountcastle sold 23,887 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total value of $597,891.61.

Privia Health Group Stock Performance

Shares of Privia Health Group stock traded down $0.83 during trading on Tuesday, hitting $22.47. 1,025,433 shares of the stock were exchanged, compared to its average volume of 813,068. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The stock’s fifty day moving average is $23.03 and its 200 day moving average is $23.60. The stock has a market cap of $2.78 billion, a PE ratio of 132.18, a P/E/G ratio of 1.49 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.21. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. During the same period last year, the firm posted $0.21 EPS. Privia Health Group’s quarterly revenue was up 17.4% compared to the same quarter last year. Sell-side analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Jefferies Financial Group restated a “buy” rating and issued a $32.00 target price on shares of Privia Health Group in a research report on Thursday, February 26th. Citigroup lowered their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Royal Bank Of Canada initiated coverage on shares of Privia Health Group in a research note on Friday, January 9th. They set an “outperform” rating and a $31.00 price objective on the stock. Stephens reaffirmed an “overweight” rating and issued a $32.00 price objective on shares of Privia Health Group in a report on Thursday, December 4th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Privia Health Group in a research report on Monday, December 29th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Privia Health Group presently has an average rating of “Moderate Buy” and an average price target of $31.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PRVA. Van Berkom & Associates Inc. raised its position in Privia Health Group by 30.1% in the third quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock worth $93,987,000 after acquiring an additional 873,344 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Privia Health Group by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after purchasing an additional 607,447 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in Privia Health Group by 139.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock valued at $19,946,000 after purchasing an additional 489,866 shares during the last quarter. Algert Global LLC boosted its holdings in Privia Health Group by 277.4% during the third quarter. Algert Global LLC now owns 484,304 shares of the company’s stock worth $12,059,000 after buying an additional 355,966 shares in the last quarter. Finally, Freestone Grove Partners LP boosted its holdings in Privia Health Group by 40.6% during the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock worth $28,768,000 after buying an additional 350,194 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.